泼尼松与甲氨蝶呤治疗初治心脏结节病
回顾性队列研究纳入61例新诊断未治疗的心脏结节病患者,分别接受泼尼松单药、甲氨蝶呤单药或两药联合治疗。中位治疗6.2个月后71.4%患者FDG PET/CT代谢应答,心肌最大标准化摄取值从6.9降至3.4(P<0.001),三组间无显著差异;随访24个月主要不良心血管事件三组分别为33.3%、20.0%、10.0%(P=0.292)。
要点
- 中位治疗6.2个月时71.4%患者达FDG PET/CT代谢应答,三组间无显著差异
- 心肌最大标准化摄取值从6.9降至3.4(P<0.001)
- 随访24个月主要不良心血管事件三组分别为33.3%、20.0%、10.0%(P=0.292),无显著差异
核心结论
- 心脏结节病患者接受泼尼松、甲氨蝶呤或联合治疗约6个月后心肌FDG摄取显著受抑,随访期间临床结局三组间无显著差异,结果需进一步研究甲氨蝶呤治疗。
研究设计与样本
- 回顾性队列研究纳入2010年1月至2017年12月间61例新诊断且未治疗的心脏结节病患者,泼尼松组21例、甲氨蝶呤组30例、联合组10例。
主要发现
- 中位治疗时长6.2[5.7-7.2]个月时71.4%患者为FDG PET/CT应答者,整体心肌最大标准化摄取值从6.9[5.0-10.1]降至3.4[2.1-4.7](P<0.001),三组间无显著差异。
- 随访24个月期间,泼尼松组7例(33.3%)、甲氨蝶呤组6例(20.0%)、联合组1例(10.0%)发生至少一次主要不良心血管事件(P=0.292)。
- 所有治疗组左心室射血分数均保持。
关键数值与推荐
- 主要结局为FDG PET/CT代谢应答,次要结局包括治疗模式、主要不良心血管事件、左心室射血分数、生物标志物及副作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出这些结果需进一步研究甲氨蝶呤在心脏结节病患者中的治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Side effects limit the long-term use of glucocorticoids in cardiac sarcoidosis (CS), and methotrexate has gained attention as steroid sparing agent although the supporting evidence is poor. This study compared prednisone monotherapy, methotrexate monotherapy or a combination of both, in the reduction of myocardial Fluorine-18 fluorodeoxyglucose (FDG) uptake and clinical stabilization of CS patients. METHODS AND RESULTS: In this retrospective cohort study, 61 newly diagnosed and treatment naïve CS patients commenced treatment with prednisone (N = 21), methotrexate (N = 30) or prednisone and methotrexate (N = 10) between January 2010 and December 2017. Primary outcome was metabolic response on FDG PET/CT and secondary outcomes were treatment patterns, major adverse cardiovascular events, left ventricular ejection fraction, biomarkers and side effects. At a median treatment duration of 6.2 [5.7-7.2] months, 71.4% of patients were FDG PET/CT responders, and the overall myocardial maximum standardized uptake value decreased from 6.9 [5.0-10.1] to 3.4 [2.1-4.7] (P < 0.001), with no significant differences between treatment groups. During 24 months of follow-up, 7 patients (33.3%; prednisone), 6 patients (20.0%; methotrexate) and 1 patient (10.0%; combination group) experienced at least one major adverse cardiovascular event (P = 0.292). Left ventricular ejection fraction was preserved in all treatment groups. CONCLUSIONS: Significant suppression of cardiac FDG uptake occurred in CS patients after 6 months of prednisone, methotrexate or combination therapy. There were no significant differences in clinical outcomes during follow-up. These results warrant further investigation of methotrexate treatment in CS patients.
引用
- Vis R, Mathijssen H, Keijsers RGM, et al. Prednisone vs methotrexate in treatment naïve cardiac sarcoidosis. J Nucl Cardiol. 2023. PMID: 36640249. doi:10.1007/s12350-022-03171-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。